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Abstract
Purpose The purpose was to evaluate the effects of long-term
anti-VEGF treatment on the retinal nerve fiber layer (RNFL)
and retinal ganglion cell layer (RGCL) thickness for patients
with neovascular AMD and glaucoma.
Methods Medical records of respective patients who had re-
ceived more than 15 anti-VEGF injections were reviewed.
Initial and latest SD-OCT macular scans were segmented
and changes of the RNFL and RGCL thickness at the four
outer ETDRS quadrants were evaluated. Secondary outcome
measures included changes of visual field parameters seen in
automated perimetry.
Results Sixteen patients were included (mean age 78
± 6 years). The mean total number of anti-VEGF injections
was 39 ± 16. Themean treatment duration was 6.1 ± 2.1 years.
The mean IOP decreased from 18 ± 5 mmHg at baseline to 15
± 5 mmHg at the last visit (p = 0.026). The mean RNFL thick-
ness volume of the outer ETDRS quadrants (0.98 ± 0.18 mm3
to 0.97 ± 0.18 mm3 p = 0.61) and its average thickness (37.9
± 7.3 μm to 37.2 ± 7.4 μm, p = 0.6) did not significantly
change. However, the average RGCL thickness decreased sig-
nificantly from 0.86 ± 0.12 mm3 to 0.79 ± 0.11 mm3
(p = 0.01), and from 27.7 ± 4.2 to 25.9 ± 3.7 μm (p = 0.01).
Number of injections correlated with the RGCL change
(r2 = 0.36, p = 0.01). The mean sensitivity, mean defect and
absolute scotomata did not significantly change with p-values
of 0.28, 0.21 and 0.07, respectively.
Conclusion Patients under long term treatment with anti-
VEGF and concurrent glaucoma show significant decrease
in macular RGLC volume. However, this decrease is compa-
rable to reported RGCL decrease in patients under anti-VEGF
treatment without underlying glaucoma and suggests that
glaucoma patients may not be at a higher risk for losing mac-
ular RNFL and RGCL, at least if adequate control of intraoc-
ular pressure is maintained.
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Introduction
Neovascular age-related macular degeneration (nAMD) is an
increasing burden in developed countries. This has made intra-
vitreal injections of anti-vascular endothelial growth factor
(anti-VEGF) agents an increasingly popular treatment method.
The anti-VEGF agents approved for clinical use such as
ranibizumab and aflibercept are known for their good safety
profile and their efficacy treating VEGF-mediated diseases
[1–3]. However continuous frequent injections, often over
many years are needed to maintain satisfying visual function.
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The fact that any intravitreal injection transiently elevates the
intraocular pressure has raised some concerns especially in pa-
tient populations with already pre-existing glaucomatous dam-
ages [4]. In fact, according to Kim et al. the IOP of eyes with a
history of glaucoma takes longer to normalize after intravitreal
drug administration [5]. Beside this well-known transient effect,
a sustained elevation of the IOP has been described in about
10% of the treated patient population [6]. It is well known that
the level of IOP is a strong risk factor for the development and/
or the progression of glaucoma; and that there is a positive
correlation of the IOP with retinal ganglion cell (RGC) damage
[7]. Even though glaucoma is diagnosed based on characteristic
optic nerve cupping with corresponding visual field (VF) de-
fects, significant loss of the RGC can occur before detectable
VF defects are evident. Structural damage can precede detect-
able functional loss by up to 5 years [8–10]. Loss of the RGC
and their axons is also known to occur in the posterior pole,
where these cells may constitute 30 to 35% of the retinal thick-
ness of the macular region [11]. Using OCT and retinal seg-
mentation tools, it is now possible to quantify respective layers
either manually or (semi)automatically [12, 13]. Since then,
several studies have been conducted to evaluate the potential
damaging effect of long term intravitreal anti-VEGF injections
on RGC by assessing the RNFL thickness in neovascular AMD
patients. Interestingly most of these studies did not find a sig-
nificant change in the RNFL thickness in neovascular AMD
patients [14, 15]. There was only one study done by Rimayanti
et al. which compared ganglion cell complex (GCC) parameters
and the thickness of the peripapillary retinal nerve fiber layer
(RNFL) between normal eyes, eyes with AMD and eyes with
AMD and glaucoma [16]. They found that the GCC was sig-
nificantly different between the normal population and the
AMD patients and that the RNFL was significantly different
between the AMD population and AMD patients with concom-
itant glaucoma. Unfortunately, their study was only cross sec-
tional and no follow-up; no long-term data on the course of the
RNFL and GCC thickness in respective groups were available.
The aim of this study was to longitudinally evaluate the
effects of long-term administration of intravitreal anti-VEGF
on the macular RNFL and retinal ganglion cell layer (RGCL)
thickness in patients with neovascular AMD and glaucoma,
which in turn would address the question whether glaucoma
patients under long-term anti-VEGF therapy require addition-
al precautions such as IOP lowering therapy before intravitreal
injections.
Materials and methods
This is a retrospective study of patients who had received
more than 15 intravitreal injections of ranibizumab or/and
aflibercept at the Department of Ophthalmology in the
University Hospital of Bern, Switzerland. Due to its
retrospective design, the study was granted a waiver to obtain
informed consent.
All medical records of patients who had the diagnosis of
neovascular AMD receiving anti-VEGF therapy between
2006 and 2015 were identified and only those with concurrent
glaucoma were included. The diagnosis of glaucoma was ei-
ther preexisting or the patient was diagnosed by a specialized
consultant during the course of the intravitreal treatment. The
inclusion criteria for glaucoma included either/or: IOP more
than 21 mmHg, and/or a cup to disc ratio (CDR) 0.5 or more
with either glaucomatous pattern visual field changes or OCT
RNFL abnormality or both. Patients with diabetes, retinal vein
occlusions, high myopia, posterior staphyloma, poor image
quality, previous vitreoretinal surgeries and with absence of
visual fields were excluded. If both eyes were eligible for the
study, the eye more severely affected by glaucoma was cho-
sen. If both eyes were equal, one of the eyes was chosen
randomly.
Until 2013 patients received a ranibizumab loading dose
followed by a capped pro-re nata (PRN) regimen with month-
ly visits and mandatory quarterly injections until July 2013
[17]. After that, all patients were treated according to the
Bern treat and extend treatment regimen [18] using either
aflibercept or ranibizumab. No paracentesis was performed
in any of the included patients with the goal to alter the
intra/postprocedural increase of IOP [19]. Visual function
was tested by counting fingers in all patients immediately after
the injection procedure.
The parameters analyzed included best corrected visual
acuity (BCVA) ETDRS letter score at 4 m, anterior segment
and posterior segment findings, intraocular pressure (IOP)
using Goldmann applanation tonometry at a fixed 3-month
interval. OCT macular scans were performed using the
Heidelberg spectral Domain (Heidelberg Engineering,
Germany) each time the patient received an intravitreal anti-
VEGF injection. The images were acquired using image align-
ment eye-tracking software (TruTrack; Heidelberg
Engineering Inc.) to obtain volumetric retinal scans with 49
parallel B-scans consisting of 512 A-scans separated by
121 μm covering an area of 20° × 20°, whereby each B-scan
was averaged nine times (automated real time repetition
rate = 9). By using the follow-up function, the exact protocol
was repeated at every visit at the same retinal location.
Baseline was defined as the time-point when the intravitre-
al therapy was commenced. For analyses, the initial and latest
macular OCTscans were selected for automatedmacular OCT
segmentations using Spectralis OCT software. In cases where
intravitreal injections were started before Heidelberg SD-OCT
was available, the initial SD-OCT performed was taken for
our analyses.
For retinal segmentation, the inbuilt Heidelberg Eye
Explorer version 1.9.10.0 (Heidelberg Engineering,
Germany) was used to measure the macular RNFL and the
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RGCL thickness. Heidelberg Eye Explorer segments 11 dif-
ferent retinal boundaries: the inner limiting membrane (ILM),
the boundaries between the RNFL and the RGCL, between
the RGCL and the inner plexiform layer (IPL), between the
IPL and the inner nuclear layer (INL), between the INL and
the outer plexiform layer (OPL), between the OPL and the
outer nuclear layer (ONL), the external limiting membrane
(ELM), two photoreceptor layers (PR1/2), the retinal pigment
epithelium (RPE), and the basal membrane (BM) with the
underlying choroid. Based on this segmentation algorithm
the area between the ILM and the RNFL segmentation line
(=mean RNFL thickness) and the area between the RNFL and
RGCL segmentation line (= mean RGCL thickness) was au-
tomatically calculated by the inbuilt software (Fig. 1).
Initially the automated inbuilt Heidelberg segmentation
software was employed. In a second step, the retinal segmen-
tations were edited manually by one author (R.S). Later, as a
final step, the segmentations were reviewed and corrected if
necessary by an independent expert grader certified by the
Bern Photographic Reading Centre (BPRC). The total
ETDRS volumes of RGCL and RNFL and the average thick-
ness of the four outer ETDRS quadrants (superior, nasal, in-
ferior, temporal and its average) were recorded at baseline and
also at the most recent visit.
Standard Automated Perimetry (SAP) was done using the
Octopus Visual Field Analyzer (Haag Streit). The parameters
such as Mean Sensitivity (MS), Mean Defect (MD) and num-
ber of absolute scotomata were recorded at the earliest and
also at the latest visit. Only patients with reliable visual fields
were included in the study. Anti-glaucomatous medication
used and changes in medication were evaluated as well.
Statistics
Statistical analyseswere performed using SPSS and GraphPad
Prism (IBM, SPSS statistics, Version 21, SPSS Inc., Chicago,
USA and GraphPad Prism, Version 6, GraphPad software
Inc., La Jolla, CA, USA). Data were analyzed using student’s
paired T-test and multivariable regression analyses. The sig-
nificance level was set at alpha ≤ 0.05. Data are given as mean
± SD.
Results
A total of 16 eyes of 16 Caucasian patients, seven males and
nine females with a mean age of 78 ± 6 years at the start of the
anti-VEGF therapy were included in the study. The mean
BCVA using the ETDRS Chart was 62 ± 15 letters at the
timepoint of treatment initiation, 63 ± 15 letters at the
timepoint of the initial RNFL and RGCL measurements and
63 ± 14 letters at the last visit. The mean change of BCVAwas
not statistically significant (p = 0.82). The mean duration of
treatment was 6.1 ± 2.1 years. The mean total number of ad-
ministered anti-VEGF injections was 39 ± 16 with a mean of
26 ± 15 ranibizumab and 13 ± 10 aflibercept injections.
The mean duration between the two OCT measurements
was 3.7 ± 1.6 years with a mean of 25 ± 14 intravitreal anti-
VEGF injections administered during this time period.
In six patients, glaucoma was diagnosed before the onset of
neovascular AMD, while in the remaining ten patients; glau-
coma was diagnosed during the anti-VEGF treatment. Three
(19%) had Pseudoexfoliative glaucoma (PXG), ten (62%)
Primary Open Angle, and three (19%) had Normal-tension
Glaucoma. In the patients without preexisting glaucoma, the
mean duration between the initiation of anti-VEGF treatment
and the onset of glaucoma was 2.4 ± 2 years. The mean IOP at
baseline was 18 ± 5 mmHg whereas at the last visit the IOP
was 15 ± 5 mmHg and this difference was statistically signifi-
cant (p = 0.026). The MS, MD and number of absolute scoto-
mata did not show any significant change over time (Table 1).
Following anti-VEGF injections, in the group with
preexisting glaucoma, three patients required additional anti-
glaucomatous eye drops and one patient received additionally
Selective Laser Trabeculoplasty (SLT) followed by a glauco-
ma filtration surgery for better IOP control; Of the ten patients
Fig. 1 Infrared image and retinal layer segmentation with optical
coherence tomography (OCT); Infrared image of the macula of a 74-
year-old female with primary open angle glaucoma, where the OCT
scan direction is shown as a green line. Representative OCT image of
inner retinal layers, where the red, dotted line represents the internal
limiting membrane, the turquoise dotted line represents the boundary
between the retinal nerve fiber layer (RNFL) and the retinal ganglion
cell layer (RGCL), and the purple, dotted line represents the boundary
between RGCL and the inner plexiform layer
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in the glaucoma treatment naïve group, nine patients needed to
be started on anti-glaucomatous eye drops. For details regard-
ing anti-glaucomatous therapy see supplemental Table 1.
The mean RNFL volume of the four outer ETDRS quad-
rants was 0.98 ± 0.18 mm3 at baseline and 0.97 ± 0.18 mm3 at
the last visit, respectively (p = 0.61), while the mean average
macular RNFL thickness of the same position at baseline was
37.9 ± 7.3 and 37.2 ± 7.4 μm at the last visit, respectively
(p = 0.6) (Fig. 2, suppl. Fig. 1). A multivariable analysis for
the potential effect of IOP at baseline, optic nerve head exca-
vation at baseline and number of administered injections on
RNFL change was not statistically significant (R2 = 0.24,
p = 0.3).
In contrast to the RNFL thickness, the RGCL of the four
outer ETDRS quadrants decreased significantly during the ob-
servational period. The RGCL volume of 0.86 ± 0.12 mm3 at
baseline decreased to 0.79 ± 0.11 mm3 (p = 0.01), at the last
visit, respectively, and the average thickness changed from
27.7 ± 4.2 μm at baseline to 25.9 ± 3.7 μm, respectively (p =
0.01), (Fig. 3). The number of administered injections between
baseline and the last visit correlated with the RGCL change
(r2 = 0.36, p = 0.01, Fig. 3, suppl. Fig. 2). The multivariable
regression analysis showed a significant effect (in order of
decreasing weight) for IOP at baseline, number of adminis-
tered injections and optic nerve head excavation on RGCL
change over time (R2 = 0.66, p = 0.004, Table 2).
Discussion
Since the introduction of intravitreal anti-VEGF injections,
increase of IOP and concurrent loss of RNFL has been a
concern for many years, especially taking into account that
patients with neovascular AMD require long-term treatment
to maintain their visual function. This concern is even more
evident in patients with already pre-existing damage, and who
may be more susceptible to IOP increase such as glaucoma
patients. In fact, Kim et al. reported that the transient IOP
increase is prolonged in glaucomatous eyes compared to eyes
without glaucomatous co-morbidity [5]. It was also stated by
Griffith and Goldberg that glaucoma patients with comorbid
retinal disease had a higher prevalence of blindness and low
vision than those without comorbid retinal disease [20].
However, Shin et al. concluded that multiple injection of
anti-VEGF did not lead to significant change in RNFL thick-
ness in wet AMD, Diabetic Retinopathy (DR) and retinal vein
occlusions (RVO) patients. IOP fluctuations and the frequency
of the injections did not appear to adversely affect RNFL
thickness. Decreased RNFL thickness, in fact, was associated
with severity of retinal ischemia in the DR and RVO patients
suggesting that inner retinal ischemia itself could be a cause of
RNFL loss rather than anti-VEGF [21].
From our study of a patient population with neovascular
AMD and concomitant glaucoma, we have found that there
was a significant decrease of RGCL over the course of long-
term anti-VEGF treatment, while the changes on macular
RNFL were not significant. So far there are no other studies
evaluating the changes of RGCL thickness in patients with
neovascular AMD and glaucoma over time. However, there
were other studies, which were done by Zucchiatti et al. and
Lee and Yu, that confirmed that the RGCL in ARMD is sig-
nificantly lower than in the normal population [22, 23].
Rimayanti et al., compared the Ganglion Cell Complex
(GCC, which consists of the nerve fiber layer, ganglion cell
layer and inner plexiform layer) and peripapillary RNFL
thickness of three different patient groups which were healthy
controls, AMD and AMD patients with glaucoma in a cross-
sectional study [16]. Interestingly, they found the average
GCC thickness to be significantly decreased in AMD eyes
compared to the healthy control eyes, whereas there was no
difference between the AMD eyes with and without glaucoma
[16]. A recent published manuscript from our group following
the RGCL and RNFL thickness of neovascular AMD patients
under long-term anti-VEGF reveal a comparable RGCL thick-
ness decrease under long-term anti-VEGF compared to our
patient population, which indicates that well-controlled
glaucomatous patients may not be at a higher risk when re-
ceiving long-term anti-VEGF treatment and may not require
additional precautions such as IOP-lowering therapy before
intravitreal injections [24]. Another possibility is that rather
AMD than anti-VEGF treatment may lead to RGCL loss,
given that a recent study found out that untreated as well as
dry AMD eyes show a reduction in RGCL thickness [22]. The
fact that the number of injections correlated with the RGCL
change suggests an association between anti-VEGF injections
and RGCL loss, but it may just describe an indirect correlation
while the direct association may be found between the dura-
tion of AMD and RGCL loss.
Age-related loss of RGCL thickness is documented to be
around 0.3–0.6% per year, while the loss of RGCL thickness
in our study was 8.5% over a mean of 3.7 years [25].
However, the visual field’s parameters had no significant
changes over time. This is in line with Quigley et al. who
did postmortem analysis of enucleated human glaucomatous
eyes and found that a 20% loss of RGC throughout the central
30° of the retina is necessary to induce a 5-dB sensitivity loss
in automated perimetry, while a 40% loss results in a 10-dB
Table 1 Mean changes of mean sensitivity, mean defect and absolute
scotoma
Indices (mean ± SD) Baseline Latest follow-up p-value
Mean sensitivity (MS) 17 ± 9 19 ± 5 0.28
Mean defect (MD) 6 ± 4 7 ± 5 0.21
Absolute scotoma (n) 4 ± 6 7 ± 10 0.07
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loss in sensitivity [9]. While the increase in absolute scotoma-
ta in our patient group may be explained by the natural course
of neovascular AMD with loss of macular photoreceptors, the
increase of theMean Defect, which reflects the overall depres-
sion of the field, may be attributed to RGCL loss [26]. The
loss of RGCL thickness in our data may be due to the under-
lying glaucoma, the administration of anti-VEGF agents or
due to the disease itself given that the multivariable analyses
identified IOP at baseline and the number of administered
injections for having the strongest effect on RGCL change
over time. Glaucoma preferentially affects the innermost reti-
nal layers: the nerve fiber, ganglion cell and inner plexiform
layers, which contain, respectively, the axons, cell bodies and
dendrites of the ganglion cells, and this is also true for AMD
[27–29]. Both AMD and glaucoma share a common patho-
genesis of neuronal cell loss via apoptosis [7, 30]. Therefore,
several studies have proven the importance of the evaluation
of the RGCL thickness in glaucoma eyes as this parameter not
only displays progression of respective disease but was also
shown to stronger correlate with visual field sensitivity than
the peripapillary RNFL thickness [31]. Tan et al. who studied
the GCC thickness in glaucoma confirmed that macular im-
aging with Fourier-domain (FD)-OCT is a useful method for
glaucoma diagnosis and has the potential for tracking glauco-
ma progression. They also claimed that the improved diagnos-
tic power of macular GCC imaging is on par with, and com-
plimentary to, peripapillary RNFL imaging [32]. Kim et al.
also agreed that macular GCC thickness and RNFL thickness
showed similar diagnostic performance for detecting early,
moderate and severe glaucoma [33]. As for AMD, studies in
the previous literature too have found a significant RGCL
complex thickness decrease in neovascular AMD eyes as well
as in patients suffering from dry AMD [22].
Themean physiological loss of RNFL thickness is around
0.18μm/year [34,35].However,ouranalysesdidnot findany
significant loss in themacular RNFLduring the observation-
alperiod.Sinceweconcentratedon theRNFLthickness in the
macular region in contrast to most of the other studies which
evaluated the peripapillary RNFL, we are unable to directly
compare the change of macular RNFL with previous pub-
lished reports. The best comparable data are provided by a
recent published study of our group. This study did not find a
significant decrease of the macular RNFL in neovascular
AMDeyes treatedwith around32 anti-VEGF injections over
a period of 45.3 months [24]. Further previously published
studies did not notice any significant alteration in the
peripapillary RNFL thickness post anti-VEGF. According
toDemirel et al., long-term treatmentwith anti-VEGFagents
did not lead to significant changes in peripapillary RNFL
thickness in wet AMD. Their follow-up was about 3 years
Fig. 2 Effect of continuous anti-vascular endothelial growth factor
(VEGF) treatment on the retinal nerve fiber layer (RNFL) in patients
with glaucoma. Co-localized infrared image of a representative patient
with average thickness of the retinal nerve fiber layer (RNFL) in each
quadrant at baseline (top) and follow-up (bottom) and RNFL thickness
development of the outer ring (OR) from baseline to follow-up (middle
panel). Box-and-whisker plots of RNFL thickness at baseline and follow-
up (bottom) (n = 16, ns not significant)
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with a mean of 13 injections [14]. Concordantly, El-Ashry
et al. stated that repeated ranibizumab injections in wet
AMD appear to have no harmful effect on the peripapillary
RNFL thickness, at least in the short-term, given that this
paper focused on the effects of the loading dose of three in-
travitreal anti-VEGF injections, and also Horsely et al. con-
cluded that long-term anti-VEGF agents did not lead to sig-
nificant changes in RNFL thickness in neovascular AMD
population. Their longest follow-up was about 2 years
(27 months), and the highest number of injections was 17.7
[15]. Another study done by Yuda et al. also noted no rela-
tionship betweenneovascularAMDandperipapillaryRNFL
thickness [29]. Thus, the abovementioned studies are in line
with our recent findings.
So far there was only one study done by Martinez-de-la-
Casa et al., who noted a significant peripapillary RNFL loss in
ARMD patients receiving intravitreal anti-VEGF after a
12 months follow-up [28]. In the study performed by
Rimayanti et al., the peripapillary RNFL was not significantly
different between AMD and normal healthy control eyes,
however glaucomatous AMD eyes showed a significantly
thinner RNFL than the AMD eyes not suffering from glauco-
ma [16].
How RGCL changes can occur without concomitant
RNFL loss remains speculative at this point as one would
assume that the loss of a ganglion cell would lead to associated
loss of its axon. One explanation may be that, since the thick-
ness and volume changes are studied in the outer macular
subfields where the RNFL contains fibers from the ganglion
cells directly subjacent to the RNFL as well as from ganglion
cells in areas farther away, the RNFL in these respective sub-
fields are more redundant and supernumerary compared to the
RGCL. This implicates that changes in the RNFL may not
only be much smaller but also lag behind those of the
RGCL and need a much longer time to be detected.
Thus, according to the literature available it remains un-
known, whether the blockage of VEGF, which is known for
its neurotrophic properties or the transient IOP increase direct-
ly after the injection procedure definitely affect the RNFL
thickness. In order to solve this question, a long-term prospec-
tive study including an age-matched control group receiving
an equal volume of intravitreal saline would be required.
However, due to ethical reasons this is difficult to obtain.
Our patient population consisting of patients suffering from
glaucoma as well as from neovascular AMD receiving long-
term anti-VEGF demonstrate that with effective control of the
IOP, no significant RNFL loss was found over a mean period
of 3.7 years. However, our patient population may not be
representative for patients suffering from progressive or se-
vere glaucoma as most of the patients were well managed,
and the IOP were very well controlled.
The limitations of this study include its retrospective design
and the small patient population, and, as such, it may be un-
derpowered to detect differences in visual field parameters.
The difficulty in segmentation of the retinal layers due to the
Table 2 The predictive parameters for retinal ganglion cell layer
(RGCL) average thickness change analyzed with a multivariable
regression analysis
Retinal ganglion cell layer (RGCL) average thickness change
Evaluated factor Partial Eta2 Model R2 p-value
IOP 0.47 0.66 0.004
N of injections 0.15
ONH excavation 0.065
IOP intraocular pressure at baseline, ONH optic nerve head
Fig. 3 Effect of continuous anti-vascular endothelial growth factor
(VEGF) treatment on the retinal ganglion cell layer (RGCL) in patients
with glaucoma. Co-localized infrared image of a representative patient
with average thickness of the retinal ganglion cell layer (RGCL) in each
quadrant at baseline (top) and follow up (bottom). Box-and-whisker plots
of RGCL thickness of the outer ring (OR) at baseline and follow up
(right) (n = 16, * = p < 0.05). Scatter plot with the correlation between
RGCL thickness change in the OR and number of injections (Pearson
correlation)
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irregular contour of retina in AMD as well as the poor demar-
cation of certain layers may contribute to errors which can
serve as confounding factors in the final result [36, 37].
Although a multivariable regression analysis was included to
determine effect variables, and a previous paper of our group
including patients with neovascular AMD under long-term
anti-VEGF treatment without glaucoma matched in terms of
age and number of administered injection served as a compa-
rable Bcontrol^ group, this study lacks a control group of
AMD patients without glaucoma on long-term anti-VEGF
and a group of AMD patients without treatment in order to
explore how much of these changes reflect the natural pro-
gression and how much can be attributed to glaucoma pro-
gression, AMD and anti-VEGF injections.
To summarize, this is the first study to longitudinally fol-
low macular RGCL and RNFL thickness in glaucomatous
patients with neovascular AMD under long-term treatment.
This study provides first evidence that well-managed
glaucomatous patients under long-term anti-VEGF treatment
may not be at a higher risk for losing macular RNFL and
RGCL than Busual^ neovascular AMD patients. However,
more conclusive evidence needs to be obtained with a larger
sample size and a prospective study design.
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